Robert J. Nelson, Cottage Grove US
Robert J. Nelson, Cottage Grove, MN US
Patent application number | Description | Published |
---|---|---|
20090093514 | IMMUNE RESPONSE MODIFIER FORMULATIONS CONTAINING OLEIC ACID AND METHODS - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 04-09-2009 |
20100120819 | METHOD OF REDUCING IMIQUIMOD IMPURITY FORMATION - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
20100120820 | METHOD OF TREATING ACTINIC KERATOSIS - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
20100120821 | METHOD OF TREATING GENITAL OR PERI-ANAL WARTS - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
20100120822 | METHOD OF CONTROLLING FORMATION OF IMIQUIMOD IMPURITIES (BHA COMPARATOR) - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
20100120823 | METHOD OF TREATING BASAL CELL CARCINOMA - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
20100120824 | METHOD OF PREPARING A PHARMACEUTICAL CREAM AND MINIMIZING IMIQUIMOD IMPURITY FORMATION - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
20100120825 | METHOD OF TREATING MOLLESCUM CONTAGIOSUM - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
20100120826 | METHOD OF INDUCING CYTOKINE BIOSYNTHESIS - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
20100120827 | X-FOLD LESS IMIQUIMOD IMPURITIES AT TWO MONTHS BETWEEN REFINED AND COMPENDIAL - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
20100120828 | METHOD OF INDUCING INTERFERON BIOSYNTHESIS - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
20100120829 | X-FOLD LESS IMIQUIMOD IMPURITIES AT SIX MONTHS BETWEEN REFINED AND COMPENDIAL - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
20100120830 | PHARMACEUTICAL CREAM HAVING SIMILAR OR LESS LEVELS OF IMIQUIMOD IMPURITY FORMATION AS CREAM WITH BHA (COMPARATOR) - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
20100120831 | METHODS FOR IMPROVING IMIQUIMOD AVAILABILITY AT TWO MONTHS, FOUR MONTHS AND SIX MONTHS BETWEEN REFINED AND COMPENDIAL - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
20100120832 | METHOD OF PREPARING A PHARMACEUTICAL CREAM AND MINIMIZING IMIQUIMOD IMPURITY FORMATION (AT LEAST FOUR MONTHS STORAGE) - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
20100120833 | METHOD OF PREPARING A PHARMACEUTICAL CREAM AND MINIMIZING IMIQUIMOD IMPURITY FORMATION (AT LEAST SIX MONTHS STORAGE) - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
20100120834 | REDUCTION OF IMIQUIMOD IMPURITIES AT FOUR MONTHS USING REFINED OLEIC ACID - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
20100120835 | PHARMACEUTICAL CREAM WITH REDUCED IMIQUIMOD IMPURITIES AT FOUR MONTHS USING REFINED OLEIC ACID - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
20100120836 | METHOD OF TREATING A DERMAL AND/OR MUCOSAL ASSOCIATED CONDITION - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
20100120837 | METHOD OF TREATING A MUCOSAL AND/OR DERMAL ASSOCIATED CONDITION - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-13-2010 |
20100130529 | METHOD OF STABILIZING IMIQUIMOD - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-27-2010 |
20100130530 | REDUCTION OF IMIQUIMOD IMPURITIES USING REFINED OLEIC ACID - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-27-2010 |
20100130531 | PHARMACEUTICAL CREAMS WITH REDUCED IMIQUIMOD IMPURITIES - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-27-2010 |
20100130532 | REDUCTION OF IMIQUIMOD IMPURITIES IN PHARMACEUTICAL CREAMS - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-27-2010 |
20100130533 | PHARMACEUTICAL CREAMS WITH REFINED OLEIC ACID - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-27-2010 |
20100130534 | METHODS FOR REDUCING IMIQUIMOD IMPURITIES FOR TWO MONTHS, FOUR MONTHS, AND SIX MONTHS - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-27-2010 |
20100130535 | METHODS FOR STABILIZING IMIQUIMOD FOR TWO MONTHS, FOUR MONTHS, AND SIX MONTHS - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-27-2010 |
20100130536 | METHODS FOR CONTROLLING FORMATION OF IMIQUIMOD IMPURITIES FOR TWO MONTHS, FOUR MONTHS, AND SIX MONTHS - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 05-27-2010 |
20120237551 | IMMUNE RESPONSE MODIFIER FORMULATIONS CONTAINING OLEIC ACID AND METHODS - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 09-20-2012 |